MetaVia's Year-End 2025 Results: Breakthroughs in Cardio-Metabolic Therapies MetaVia Inc. shares promising 2025 financial results with key advances in its cardiometabolic innovations, highlighting positive outcomes for DA-1726 and vanoglipel.

MetaVia's Year-End 2025 Results: Breakthroughs in Cardio-Metabolic Therapies #USA #Cambridge #MetaVia_Inc. #DA-1726 #Vanoglipel

MetaVia Broadens Global Patent Protection for Vanoglipel Until 2035 MetaVia Inc. enhances its patent portfolio for vanoglipel, supporting treatments for metabolic and liver diseases, effective through 2035. Explore their strategic advancements.

MetaVia Broadens Global Patent Protection for Vanoglipel Until 2035 #USA #Cambridge #MetaVia #GPR119 #Vanoglipel

MetaVia Showcases Innovative Therapies for Obesity at Life Sciences Investor Forum Join MetaVia Inc. at the Life Sciences Virtual Investor Forum where they will unveil groundbreaking therapies aimed at tackling obesity and metabolic disorders, featuring a live Q&A session.

MetaVia Showcases Innovative Therapies for Obesity at Life Sciences Investor Forum #USA #Cambridge #MetaVia #DA-1726 #Vanoglipel

MetaVia Unveils Promising AI-Modeling Outcomes Confirming Therapeutic Aims for Vanoglipel MetaVia's latest AI-driven collaboration reveals significant targets for the drug vanoglipel, addressing inflammatory and cardiometabolic diseases. Discover the promising results.

MetaVia Unveils Promising AI-Modeling Outcomes Confirming Therapeutic Aims for Vanoglipel #United_States #Cambridge #MetaVia #Vanoglipel #AI-Modeling

MetaVia Reports Significant Phase 2a Findings for Vanoglipel in MASH Patients at AASLD 2025 MetaVia Inc. highlights promising Phase 2a data on vanoglipel, showcasing its efficacy in treating patients with presumed MASH during the AASLD Liver Meeting 2025.

MetaVia Reports Significant Phase 2a Findings for Vanoglipel in MASH Patients at AASLD 2025 #United_States #Washington_D.C. #MetaVia #Vanoglipel #Phase_2a_Data

MetaVia to Showcase Groundbreaking Liver Treatment Research at AASLD 2025 MetaVia Inc. will present promising data on Vanoglipel (DA-1241), a novel GPR119 agonist, at the upcoming AASLD Liver Meeting 2025, detailing its hepatoprotective effects.

MetaVia to Showcase Groundbreaking Liver Treatment Research at AASLD 2025 #United_States #Washington,_D.C. #MetaVia #GPR119 #Vanoglipel